In either case, the overexpression of FOLR1 was reported in serous ovarian carcinoma describing clinicopathological characteristics and outcomes, as well as the relationship between FOLR1 and chemoresistance [50]. This evidence concerns the gene FOLR1 and ovarian serous carcinoma.